{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:46:43Z","timestamp":1767851203342,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ijid.2021.10.032","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T22:17:35Z","timestamp":1634854655000},"page":"282-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-7033","authenticated-orcid":false,"given":"Anuja","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parth","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigar","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasimahmed","family":"Sachora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpesh","family":"Sukhwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipesh","family":"Sorathiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parin","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adit","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.10.032_bib0001","unstructured":"Angyal A, Longet S, Moore S, Payne RP, Harding A, Tipton T, et\u00a0al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study. Available at SSRN: https:\/\/ssrn.com\/abstract=3812375 or 10.2139\/ssrn.3812375"},{"key":"10.1016\/j.ijid.2021.10.032_bib0002","doi-asserted-by":"crossref","unstructured":"Asrani P, Eapen MS, Hassan MI, Sohal SS. Implications of the second wave of COVID-19 in India. The Lancet Respiratory Medicine 2021 Jun 30.","DOI":"10.1016\/S2213-2600(21)00312-X"},{"issue":"3","key":"10.1016\/j.ijid.2021.10.032_bib0003","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1473-3099(21)00081-5","article-title":"The world's largest COVID-19 vaccination campaign","volume":"21","author":"Bagcchi","year":"2021","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.ijid.2021.10.032_bib0004","unstructured":"Bhattacharya A. June 11, 2021. COVID-19: deaths in 2nd wave cross 2 lakh at daily average of over 2000. The Times of India. https:\/\/timesofindia.indiatimes.com\/india\/covid-19-deaths-in-2nd-wave-cross-2-lakh-at-daily-average-of-over-2000\/articleshow\/83414459.cms"},{"key":"10.1016\/j.ijid.2021.10.032_bib0005","unstructured":"COVID-19 vaccine tracker and landscape. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. Accessed on July 26, 2021."},{"issue":"15","key":"10.1016\/j.ijid.2021.10.032_bib0006","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ijid.2021.10.032_bib0007","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","author":"Ella","year":"2021","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.ijid.2021.10.032_bib0008","doi-asserted-by":"crossref","unstructured":"Ella R, Vadrevu KM, Jogdand H, Prasad SD, Reddy S, Sarangi V, et\u00a0al. Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind, randomised control trial. 10.1016\/S1473-3099(20)30942-7 (2021).","DOI":"10.2139\/ssrn.3747047"},{"key":"10.1016\/j.ijid.2021.10.032_bib0009","unstructured":"Government of India COVID-19 dashboard. https:\/\/www.mygov.in\/covid-19. (Accessed July 6, 2021)"},{"key":"10.1016\/j.ijid.2021.10.032_bib0010","unstructured":"India: WHO Coronavirus Disease (COVID-19) Dashboard. https:\/\/covid19.who.int\/region\/searo\/country\/in (accessed July 1, 2021)"},{"key":"10.1016\/j.ijid.2021.10.032_bib0011","unstructured":"(Recovery or Death) in India \u2014 Coronavirus Cases \u2014 Worldometer. https:\/\/www.worldometers.info\/coronavirus\/country\/india (accessed July 1, 2021)"},{"key":"10.1016\/j.ijid.2021.10.032_bib0012","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.dsx.2021.05.009","article-title":"Differences between first wave and second wave of COVID-19 in India","volume":"15","author":"Jain","year":"2021","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"10.1016\/j.ijid.2021.10.032_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24579-7","article-title":"Immune responses to a single dose of the AZD1222\/Covishield vaccine in health care workers","volume":"12","author":"Jeewandara","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.ijid.2021.10.032_bib0014","doi-asserted-by":"crossref","unstructured":"Kale P, Gupta E, Bihari C, Patel N, Rooge S, Pandey A, et\u00a0al. Clinicogenomic analysis of breakthrough infections by SARS CoV2 variants after ChAdOx1 nCoV-19 vaccination in healthcare workers. medRxiv 2021, Jan 1.","DOI":"10.1101\/2021.06.28.21259546"},{"issue":"10286","key":"10.1016\/j.ijid.2021.10.032_bib0015","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(21)01052-7","article-title":"India's COVID-19 emergency","volume":"397","author":"Lancet","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.10.032_bib0016","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants","volume":"33","author":"MacDonald","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2021.10.032_bib0017","unstructured":"Ministry of Home Affairs (2021). Guidelines for effective control of COVID-19. https:\/\/www.mha.gov.in\/sites\/default\/files\/MHAOrder_23032021.pdf."},{"key":"10.1016\/j.ijid.2021.10.032_bib0018","doi-asserted-by":"crossref","unstructured":"Pujari BS and Shekatkar SM. Multi-city modelling of epidemics using spatial networks: Application to 2019-nCov (COVID-19) coronavirus in India. medRxiv 2020. doi: 10.1101\/2020.03.13.20035386","DOI":"10.1101\/2020.03.13.20035386"},{"key":"10.1016\/j.ijid.2021.10.032_bib0019","doi-asserted-by":"crossref","unstructured":"Ramakrishnan M, Subbarayan P. Impact of vaccination in reducing hospital expenses, mortality and average length of stay among COVID 19 patients. A retrospective cohort study from India. medRxiv 2021, Jan 1.","DOI":"10.1101\/2021.06.18.21258798"},{"key":"10.1016\/j.ijid.2021.10.032_bib0020","doi-asserted-by":"crossref","unstructured":"Ranjan R, Sharma A, Verma MK. Characterization of the second wave of COVID-19 in India. medRxiv 2021, Jan 1.","DOI":"10.1101\/2021.04.17.21255665"},{"issue":"23","key":"10.1016\/j.ijid.2021.10.032_bib0021","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26. COV2. S vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.ijid.2021.10.032_bib0022","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/vaccines9020160","article-title":"COVID-19 vaccine hesitancy worldwide \u2014 a concise systematic review of vaccine acceptance rates","volume":"9","author":"Sallam","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ijid.2021.10.032_bib0023","unstructured":"Singh R and Adhikari R 2020. Age-structured impact of social distancing on the COVID-19 epidemic in India. arXiv 2003;12055."},{"key":"10.1016\/j.ijid.2021.10.032_bib0024","article-title":"Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel","author":"Swift","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ijid.2021.10.032_bib0025","doi-asserted-by":"crossref","first-page":"n1124","DOI":"10.1136\/bmj.n1124","article-title":"Why is India having a COVID-19 surge?","volume":"373","author":"Thiagarajan","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ijid.2021.10.032_bib0026","first-page":"1007","article-title":"Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes and Metabolic Syndrome","volume":"15","author":"Tyagi","year":"2021","journal-title":"Clinical Research and Reviews"},{"key":"10.1016\/j.ijid.2021.10.032_bib0027","unstructured":"Vaccine information, ICMR New Delhi-COVID-19 vaccine. https:\/\/vaccine.icmr.org.in\/covid-19-vaccine (accessed July 17, 2021)."},{"issue":"10285","key":"10.1016\/j.ijid.2021.10.032_bib0028","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study","volume":"397","author":"Vasileiou","year":"2021","journal-title":"The Lancet"},{"issue":"10269","key":"10.1016\/j.ijid.2021.10.032_bib0029","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.10.032_bib0030","unstructured":"Weekly epidemiological update on COVID-19 \u2014 29 June 2021, Edition 46; Emergency situational updates."},{"key":"10.1016\/j.ijid.2021.10.032_bib0031","unstructured":"World Health Organization. Director General's opening remarks. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19\u201411-march-2020 (accessed July 15, 2021)."}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221008195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221008195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:07:46Z","timestamp":1761120466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221008195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"alternative-id":["S1201971221008195"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.10.032","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}